Mechanisms of colitis-accelerated colon carcinogenesis and its prevention with the combination of aspirin and curcumin: Transcriptomic analysis using RNA-seq

Biochemical Pharmacology

Volumn 135, Issue , 2017, Pages 22-34

  Guo, Yue ^a   Su, Zheng Yuan ^a,b   Zhang, Chengyue ^a   Gaspar, John M ^a   Wang, Rui ^a,c   Hart, Ronald P ^d   Verzi, Michael P ^d   Kong, Ah Ng Tony ^a  

^a RUTGERS UNIVERSITY   (United States)

^b CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^c Shanghai Roche Pharmaceutucals Ltd   (China)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Aspirin; Colitis associated colorectal cancer; Curcumin; RNA seq

Indexed keywords

ACETYLSALICYLIC ACID; AZOXYMETHANE; CURCUMIN; DEXTRAN SULFATE; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; COLITIS; COLITIS ACCELERATED COLORECTAL CANCER; COLON CARCINOGENESIS; COLON TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ACTIVITY; GENE; GENE EXPRESSION; HISTOLOGY; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SEQUENCE; ANIMAL; C57BL MOUSE; COLONIC NEOPLASMS; COMBINATION DRUG THERAPY; GENE EXPRESSION PROFILING; GENETICS; PATHOLOGY; PROCEDURES; SEQUENCE ANALYSIS;

ANIMALS; ASPIRIN; COLITIS; COLONIC NEOPLASMS; CURCUMIN; DRUG THERAPY, COMBINATION; GENE EXPRESSION PROFILING; MICE; MICE, INBRED C57BL; SEQUENCE ANALYSIS, RNA;

EID: 85016183883     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2017.02.021     Document Type: Article

References (61)

1. N. Howlader, A. Noon, M. Krapcho, SEER Cancer Statistics Review, In Institute, N.C. (ed.), 2012.
2. Hanahan, D., et al. Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
3. Lasry, A., et al. Inflammatory networks underlying colorectal cancer. Nat. Immunol. 17 (2016), 230–240.
4. Feagins, L.A., et al. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 6 (2009), 297–305.
5. Soderlund, S., et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 136 (2009), 1561–1567 quiz 1818–9.
6. De Robertis, M., et al. The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy studies. J. Carcinog., 10, 2011, 9.
7. Sporn, M.B., et al. Chemoprevention: an essential approach to controlling cancer. Nat. Rev. Cancer 2 (2002), 537–543.
8. Garcia-Albeniz, X., et al. Aspirin for the prevention of colorectal cancer. Best Pract. Res. Clin. Gastroenterol. 25 (2011), 461–472.
9. Algra, A.M., et al. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13 (2012), 518–527.
10. Burn, J., et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378 (2011), 2081–2087.
11. Velayos, F.S., et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 130 (2006), 1941–1949.
12. Guo, Y., et al. The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice. Carcinogenesis 37 (2016), 616–624.
13. Guo, Y., et al. Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1. Biochem. Pharmacol. 94 (2015), 69–78.
14. Murphy, E.A., et al. Curcumin's effect on intestinal inflammation and tumorigenesis in the ApcMin/+ mouse. J. Interferon Cytokine Res. 31 (2011), 219–226.
15. Carroll, R.E., et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev. Res. (Phila) 4 (2011), 354–364.
16. Pereira, M.A., et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 17 (1996), 1305–1311.
17. Rao, C.V., et al. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 14 (1993), 2219–2225.
18. Vareed, S.K., et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol. Biomarkers Prev. 17 (2008), 1411–1417.
19. Lu, G., et al. Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin. Clin. Cancer Res. 14 (2008), 4981–4988.
20. Zheng, X., et al. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev. Res. (Phila) 3 (2010), 114–124.
21. Yue, W., et al. Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget 6 (2015), 21208–21224.
22. Liu, Y., et al. Effects of combination of calcium and aspirin on azoxymethane-induced aberrant crypt foci formation in the colons of mice and rats. Nutr. Cancer 60 (2008), 660–665.
23. Thakkar, A., et al. The molecular mechanism of action of aspirin, curcumin and sulforaphane combinations in the chemoprevention of pancreatic cancer. Oncol. Rep. 29 (2013), 1671–1677.
24. Perkins, S., et al. Age-related difference in susceptibility of Apc(Min/+) mice towards the chemopreventive efficacy of dietary aspirin and curcumin. Br. J. Cancer 88 (2003), 1480–1483.
25. Park, W., et al. New perspectives of curcumin in cancer prevention. Cancer Prev. Res. (Phila) 6 (2013), 387–400.
26. Wang, Z., et al. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10 (2009), 57–63.
27. Cheung, K.L., et al. Differential in vivo mechanism of chemoprevention of tumor formation in azoxymethane/dextran sodium sulfate mice by PEITC and DBM. Carcinogenesis 31 (2010), 880–885.
28. Kim, D., et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol., 14, 2013, R36.
29. Trapnell, C., et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28 (2010), 511–515.
30. Murthy, S.N., et al. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig. Dis. Sci. 38 (1993), 1722–1734.
31. Kubota, M., et al. Preventive effects of curcumin on the development of azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db obese mice. Nutr. Cancer 64 (2012), 72–79.
32. Huang, M.T., et al. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 54 (1994), 5841–5847.
33. Tian, Y., et al. Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. Int. J. Colorectal Dis. 26 (2011), 13–22.
34. Suzuki, R., et al. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis 27 (2006), 162–169.
35. Choi, H.A., et al. Interaction of over-the-counter drugs with curcumin: influence on stability and bioactivities in intestinal cells. J. Agric. Food Chem. 60 (2012), 10578–10584.
36. Dinis, T.C., et al. Action of phenolic derivatives (acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of membrane lipid peroxidation and as peroxyl radical scavengers. Arch. Biochem. Biophys. 315 (1994), 161–169.
37. Gialeli, C., et al. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278 (2011), 16–27.
38. Polistena, A., et al. MMP7 expression in colorectal tumours of different stages. In Vivo 28 (2014), 105–110.
39. Koskensalo, S., et al. MMP-7 as a prognostic marker in colorectal cancer. Tumour Biol. 32 (2011), 259–264.
40. Klupp, F., et al. Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients. BMC Cancer, 16, 2016, 494.
41. Koller, F.L., et al. Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia. Lab. Invest. 92 (2012), 1749–1759.
42. Wang, D., et al. The role of chemokines in intestinal inflammation and cancer. Curr. Opin. Pharmacol. 9 (2009), 688–696.
43. Gijsbers, K., et al. CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. Eur. J. Immunol. 34 (2004), 1992–2000.
44. Rubie, C., et al. ELR+ CXC chemokine expression in benign and malignant colorectal conditions. BMC Cancer, 8, 2008, 178.
45. Kummola, L., et al. Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa. BMC Cancer, 5, 2005, 41.
46. Zhang, J., et al. Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP-WT1-TBL1 axis. Gut 65 (2016), 1482–1493.
47. Yang, G.Z., et al. Prognostic value of carbonic anhydrase VII expression in colorectal carcinoma. BMC Cancer, 15, 2015, 209.
48. Dai, H.Y., et al. Carbonic anhydrase III promotes transformation and invasion capability in hepatoma cells through FAK signaling pathway. Mol. Carcinog. 47 (2008), 956–963.
49. Kang, N., et al. Hepatic stellate cells: partners in crime for liver metastases?. Hepatology 54 (2011), 707–713.
50. Ye, Y., et al. Up-regulation of REG3A in colorectal cancer cells confers proliferation and correlates with colorectal cancer risk. Oncotarget 7 (2016), 3921–3933.
51. Garg, P., et al. Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res. 70 (2010), 792–801.
52. Chang, L.Y., et al. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 72 (2012), 1092–1102.
53. Ihara, A., et al. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J. Pharmacol. Sci. 103 (2007), 24–32.
54. MacFie, T.S., et al. DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid. Inflamm. Bowel Dis. 20 (2014), 514–524.
55. Mukai, S., et al. Overexpression of transmembrane protein BST2 is associated with poor survival of patients with esophageal, gastric, or colorectal cancer. Ann. Surg. Oncol., 2016.
56. Jung, C., et al. HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. Br. J. Cancer 92 (2005), 2233–2239.
57. Yang, Z., et al. Epigenetic inactivation and tumor-suppressor behavior of NGFR in human colorectal cancer. Mol. Cancer Res. 13 (2015), 107–119.
58. Sui, Y., et al. Inhibition of TMEM16A expression suppresses growth and invasion in human colorectal cancer cells. PLoS ONE, 9, 2014, e115443.
59. Barrett, C.W., et al. Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma. Cancer Res. 73 (2013), 1245–1255.
60. Hryniuk, A., et al. Cdx1 and Cdx2 function as tumor suppressors. J. Biol. Chem. 289 (2014), 33343–33354.
61. Baba, Y., et al. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin. Cancer Res. 15 (2009), 4665–4673.